Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.